(OTLK)
NCM – Real Time Price. Currency in USD
0.21
-0.00 (-0.90%)
At close: Mar 27, 2026, 4:00 PM EDT
0.21
+0.00 (0.19%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
0.21
-0.00 (-0.90%)
At close: Mar 27, 2026, 4:00 PM EDT
0.21
+0.00 (0.19%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
| Name | Position |
|---|---|
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development & Regulatory Affairs |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs |
| Mr. Jedd Comiskey | Senior VP - Head of Europe |
| Mr. Joel Prieve | Senior Vice President of Licensing and M&A |
| Mr. Lawrence A. Kenyon CPA | EVP, CFO, Treasurer, Secretary & Director |
| Mr. Robert Charles Jahr | President, CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-03-16 | 8-K | tm268874d1_8k.htm |
| 2026-03-11 | 8-K | tm268371d1_8k.htm |
| 2026-03-10 | 8-K | tm268371d2_8k.htm |
| 2026-03-05 | 8-K | tm268164d1_8k.htm |
| 2026-01-26 | DEF 14A | ny20058729x1_def14a.htm |
| 2026-01-02 | 8-K | tm2534608d1_8k.htm |
| 2025-12-19 | 10-K | otlk-20250930x10k.htm |
| 2025-11-13 | 8-K | tm2531109d1_8k.htm |
| 2025-11-03 | 8-K | tm2530088d1_8k.htm |
| 2025-09-29 | 8-K | tm2527376d1_8k.htm |